AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02215941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 8% ointment
Study NCT02215941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00262054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
Study NCT00744900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin
Description: Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
Study NCT03050580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-esteem enhancement group
Description: Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
Study NCT03050580 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for abused women
Description: The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
Study NCT01228123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RRT for acute kidney failure using the CVVH method
Description: patients randomized to receive CVVH
Study NCT01228123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RRT for acute kidney failure using the IHD (intermittent HD)
Description: patients randomized to receive IHD
Study NCT04009993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-BIRTHPERFORM digital tool
Description: use of A-BIRTHPERFORM digital tool
Study NCT04269109 — intervention group
Intervention type: OTHER
Intervention: Multi-modal Opioid Sparing Pain Management Protocol
Description: Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
Study NCT02281019 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP (Endoscopic Retrograde Cholangiopancreatography)
Description: ERCP procedure will be performed to visualize bile ducts.
Study NCT02281019 — intervention group
Intervention type: DEVICE
Intervention: SpyGlass DVS and SpyGlass Digital Simple (DS)
Description: Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
Study NCT01656863 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT03056118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month dual anti-platelet therapy
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
Study NCT03056118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month dual anti-platelet therapy
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
Study NCT03056118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Zotarolimus eluting stent is applied to coronary stenotic lesion
Study NCT03056118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus eluting stent
Description: Biolimus eluting stent is applied to coronary stenotic lesion
Study NCT03104725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Oral
Study NCT03104725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).
Study NCT03104725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: If needed for lumbar puncture
Study NCT01358903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Cohorts receiving multiple escalating doses iv
Study NCT01358903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
Study NCT03604445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 905677
Description: Solution for infusion
Study NCT03654846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmergencyEye
Description: EmergencyEye Smartphone App
Study NCT00440505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Study NCT00440505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (5 mg)
Description: Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
Study NCT00440505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (10 mg)
Description: Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
Study NCT04617158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adjustable strabismus surgery
Description: Adjustable surgery will be done using sliding nose technique using fornix approach
Study NCT00262054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Un-fractionated heparin
Description: UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
Study NCT00300742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate up to 300 mg per day.
Study NCT03558880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Erector Spinae Plane Block was performed
Study NCT03558880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumescent Anesthesia
Description: Tumescent Anesthesia was applied
Study NCT02468245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weekly telephone follow up
Description: For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
Study NCT02468245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
Study NCT00294762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: oral tablet
Study NCT00294762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV
Study NCT00294762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV
Study NCT00846950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexchlorpheniramine, lorazepam
Study NCT04022395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: stress cardiac MRI
Description: pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
Study NCT05056584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucagon infusion
Description: One hour glucagon-clamp followed by one hour of blood sampling
Study NCT05056584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Primed tracer infusion
Description: Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,
Study NCT01753908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broccoli Sprout Extract
Description: Given PO
Study NCT01753908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01753908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01753908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Urinary ITCs and metabolites measured
Study NCT01753908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Urinary ITCs and metabolites measured
Study NCT01753908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03391947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: semilunar coronally positioned flap
Description: The description of this intervention has been already given before
Study NCT03391947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap
Description: The description of this intervention has been already given before
Study NCT00215605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
Study NCT02849639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive educational materials, but will not receive MTM.
Study NCT02849639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Therapy Management (MTM)
Description: Participants will receive MTM in addition to the educational materials.
Study NCT02849639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine patch
Description: At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
Study NCT02849639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Scopolamine patch
Description: At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
Study NCT01006070 — intervention group
Intervention type: PROCEDURE
Intervention: kyphoplasty
Description: surgical kyphoplasty
Study NCT04855994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: The investigators performed Paravertebral block to that patient group for postoperative analgesia
Study NCT04855994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectoral block
Description: The investigators performed pectoral block to that patient group for postoperative analgesia
Study NCT04213859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRET - Virtual Reality Exposure Therapy
Description: VRET will include 4 weekly 1-hour sessions over the course of 4 weeks. The treatment protocol is based on the Virtual Reality (VR) treatment manual guidelines (Rothbaum \& Hodges, 1997,1999) and includes psychoeducation, anxiety management training, cognitive restructuring and exposure. The first therapy session focuses on creating an individually-tailored conceptualization and treatment plan. Following this process, participant and therapist conduct a short introductory VR flight exposure simulation to familiarize the participant with the VRET apparatus. The VRET apparatus is an advanced, large-scale VR system that allows maximal immersion within the virtual environment. The second, third and fourth sessions include psychoeducation, relaxation training, cognitive restructuring and individually-tailored VR exposures (the therapist can manipulate the turbulence level and other flight-related variables to fit participants' fears and current progress).
Study NCT02765451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interventions of the Cancéropôle Nord-Ouest
Description: During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,.....
Study NCT01825031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
Study NCT01825031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: 100mg once daily for 12 weeks
Study NCT01825031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: 500mg once daily for 5 days
Study NCT01825031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: a single dose 400mg
Study NCT01825031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: 300mg taken immediately in combination with cotrimoxazole
Study NCT01825031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Supplementary Food
Description: 2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
Study NCT00816374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reading materials and discussions
Description: We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~* The American Cancer Society~* The American Academy of Dermatology~* The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~* Sun protection practices~* Risk factors for melanoma~* Information about what melanoma looks like~* How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets.
Study NCT00816374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reading materials and discussions
Description: We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~* Melanoma and skin cancer protection guidelines~* The benefits of skin screening practices~* Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets.
Study NCT00816374 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~* knowledge of melanoma~* current and past skin cancer screening practices~* current and past sun protection practices~* attitudes about skin cancer and sun protection~* feelings about relative's melanoma diagnosis and treatment
Study NCT04233749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets
Description: 325mg of tranexamic acid twice daily for six months
Study NCT04202731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBS Study
Description: Sleep extension intervention
Study NCT01903499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Bean patty
Study NCT01903499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other: Beef patty
Study NCT00243659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReFacto AF
Study NCT03299920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized instructions
Description: Specific instructions related to peripheral nerve block.
Study NCT03299920 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional instructions
Description: Usual post-operative instructions.
Study NCT01975168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handylaser Trion laser acupuncture
Description: intervention interval is 3 times per week for 12 weeks
Study NCT01975168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Handylaser Trion laser acupuncture
Description: intervention interval is 3 times per week for 12 weeks
Study NCT04446364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanolic extract of Aloe vera gel cavity disinfectant
Description: Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
Study NCT04446364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ethanolic extract of Aloe vera gel cavity disinfectant
Description: Application of Aloe vera gel after partial caries removal then taking dentin bacterial sample to be sure for reduction of bacterial count (streptococcus mutans and Lactobacillus) in deep cavity then add final restoration
Study NCT04446364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorohexadine
Description: 2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
Study NCT04446364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorohexadine
Description: 2%Chlorohexadine add on deep cavity as cavity disinfection after partial caries removal. Pre and post excavation bacterial count to measure bacterial reduction then add final restoration
Study NCT02788864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterakine (DHA/piperaquine)
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Study NCT02788864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Stage 1: Parasite Clearance~* Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~* Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
Study NCT00755833 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 50
Description: Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
Study NCT00038350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lingual Strengthening
Description: 8 week lingual strengthening exercise protocol